Latest News and Press Releases

Examines the evolving competitive landscape, regulatory developments & investment trends shaping the future of chronic kidney disease management worldwide.

R1 Therapeutics establishes world-class Scientific Advisory Board to support advancement of AP306 in Chronic Kidney Disease

Austin, TX, USA, June 25, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Therapeutic Apheresis Market Size, Trends and Insights By Product Type (Apheresis...

Growing role of machine learning, deep learning and predictive analytics in addressing clinical, operational and economic challenges in kidney care.

Partnership strengthens Istios Health’s network while expanding access to nephrology expertise and cutting-edge research for hospitals and patients.

EMPAVELI® (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced...

EMPAVELIMD (pegcétacoplan) est le premier traitement autorisé dans le traitement des patients adultes et pédiatriques de 12 ans et plus atteints de glomérulopathie à dépôts de C3 (GC3) ou de...

R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia.

Istios Health announced a partnership with Penn Highlands Healthcare to deliver comprehensive virtual nephrology care across its hospital system.

Istios Health Expands Into Nephrology With Three Practice Partnerships in the Northeast